Biopsy and Drainage · IR Playbook

Transjugular Renal Biopsy (TJRB)

Transjugular renal biopsy obtains non-targeted renal cortical tissue through a renal vein, usually from a right lower-pole cortical vein, without a direct percutaneous renal puncture. It is reserved for patients who require histologic diagnosis but have a contraindication to or failed percutaneous biopsy, particularly those with high bleeding risk or inability to tolerate prone positioning. A 2020 systematic review reported diagnostic tissue in 90.3%, minor bleeding in 18.2%, and major bleeding requiring transfusion or intervention in 4.5%; the transjugular route reduces bleeding risk in appropriately selected high-risk patients but does not eliminate it.

Learning objectives

• Select patients in whom transjugular biopsy offers a safer or technically feasible alternative to percutaneous renal biopsy.
• Navigate from the internal jugular vein to a peripheral lower-pole renal cortical vein and orient the biopsy away from the hilum and adjacent bowel.
• Obtain and correctly triage cortical cores for light microscopy, immunofluorescence and electron microscopy.
• Recognize capsular perforation, hematuria and major hemorrhage and initiate endovascular or supportive management promptly.

Indications

• Need for non-targeted native renal cortical biopsy when percutaneous biopsy is contraindicated because of coagulopathy, thrombocytopenia or antithrombotic therapy that cannot safely be interrupted.
• Morbid obesity, massive ascites, severe respiratory compromise, mechanical ventilation or another condition that makes prone percutaneous biopsy unsafe or technically impractical.
• Solitary functioning kidney, small or anomalously positioned kidney, or horseshoe kidney when multidisciplinary review considers the percutaneous route unacceptably risky.
• Failed or nondiagnostic percutaneous renal biopsy when repeat histology remains clinically necessary.
• Need for combined transjugular renal and liver biopsy during the same session, including selected patients with combined hepatic and renal disease.
• Selected patients requiring simultaneous dialysis-catheter placement and renal biopsy when this reduces the risk or burden of separate procedures.

Absolute contraindications

• Thrombosis of the intended renal vein or absence of a traversable central and renal venous route.
• No clinical indication for random renal biopsy or inability to obtain informed consent in a non-emergency setting.

Relative contraindications

• Uncontrolled severe hypertension.
• Hydronephrosis with markedly thinned cortex, severely atrophic kidneys or no suitable peripheral cortical vein.
• Severe iodinated-contrast hypersensitivity or inability to tolerate even minimized contrast without an acceptable alternative strategy.
• Active systemic infection or unstable cardiopulmonary status.
• Uncorrected hemostatic derangement beyond the team's agreed risk threshold; TJRB permits biopsy in selected high-risk patients but is not bloodless.
• Suspected focal renal mass, for which a targeted image-guided biopsy route is generally required.

Equipment

• Ultrasound machine with sterile high-frequency linear transducer cover for internal jugular access.
• Micropuncture venous-access set with 21 G needle, 0.018-inch wire and 4–5 Fr introducer.
• 8–9 Fr short internal-jugular introducer sheath.
• 5 Fr multipurpose angiographic catheter, approximately 65 cm, with alternative angled catheter available.
• 0.035-inch, 180 cm hydrophilic guidewire and 0.035-inch tight-J Rosen-type wire.
• 9 Fr × 45 cm long vascular sheath or compatible transjugular biopsy introducer.
• 18–19 G, 60–70 cm side-cut transjugular core-biopsy needle system with a protective catheter or cannula.
• Low-osmolar iodinated contrast, dilute contrast syringes and fluoroscopic angiography equipment.
• Sterile specimen board and separately labeled containers or media for LM, IF and EM according to the renal pathology protocol.
• Gelatin sponge pledgets or slurry and appropriately sized coils for tract or venous-branch embolization when required.
• Renal arterial angiography and microcatheter embolization equipment immediately available for major arterial bleeding.

Procedure steps

1. Reconfirm the indication, target kidney, venous patency, antithrombotic plan and blood-product availability. Speak directly with renal pathology about LM, IF and EM allocation before opening the biopsy device.Pearl: When tissue is scant, immediate renal-pathologist triage prevents loss of the only diagnostic glomeruli.
2. Position the patient supine, apply standard monitoring, and prep the neck and upper chest. Under real-time ultrasound, puncture the right internal jugular vein and place an 8–9 Fr introducer using micropuncture access.Pearl: Confirm venous patency and visualize the needle tip continuously.
3. Advance a 5 Fr multipurpose catheter and 0.035-inch wire through the right atrium into the IVC under fluoroscopy. Select the right renal vein and perform a gentle venogram to define the main vein and lower-pole branches.Pearl: Withdraw or reposition the wire if sustained ectopy occurs during right-atrial passage.
4. Catheterize a peripheral lower-pole renal vein and gently inject a small volume of dilute contrast. Choose a branch that creates a wedge-shaped cortical blush and permits a posterolateral trajectory.Pearl: The lower pole offers favorable sheath alignment and keeps the biopsy away from the hilum.
5. Place a 180 cm tight-J Rosen-type wire securely in the selected branch and advance the 9 Fr × 45 cm sheath into the lower-pole renal vein under fluoroscopy. Stop if the sheath buckles, straightens the vein excessively or meets resistance.Pearl: A tight-J wire reduces the risk of peripheral venous and capsular perforation.
6. Advance the protected 18–19 G side-cut biopsy system through the sheath to its tip. Rotate the cannula so the throw will pass posterolaterally into renal cortex, away from the hilum, collecting system and bowel.Pearl: Keep the cutting needle protected until the assembly is fully positioned.
7. Stabilize the sheath and deploy the side-cut needle into the cortex under fluoroscopy. Withdraw the needle without losing distal venous access and immediately inspect the core for cortical tissue.Pearl: The first passes often provide the best-preserved tissue; prioritize accuracy rather than a high pass count.
8. Hand each core immediately to renal pathology or trained staff. Allocate tissue for light microscopy, immunofluorescence and electron microscopy according to the pre-agreed protocol, confirming that cortex and glomeruli are present whenever on-site assessment is available.Pearl: On-site adequacy assessment can reduce unnecessary additional passes.
9. After each pass, perform a low-pressure check venogram for capsular perforation or persistent extravasation. Repeat only until adequate tissue has been obtained, balancing the need for LM, IF and EM against the increasing bleeding risk of additional passes.Pearl: If on-site renal pathology is unavailable, several cores may be needed, but there is no universal pass number; individualize to tissue quality and bleeding risk.
10. If limited capsular staining is seen and the patient is stable, maintain access and reassess because isolated perforation is often self-limited. For persistent extravasation, worsening hematuria or hemodynamic change, embolize the biopsy tract or injured venous branch with gelatin sponge or coils and evaluate for an arterial source.Pearl: Do not remove access until persistent bleeding has been excluded or treated.
11. Perform a final renal venogram, remove the renal and jugular sheaths, and obtain jugular hemostasis with manual compression. Document the kidney and branch sampled, needle type, number of passes and cores, pathology allocation, venographic findings and any embolization.

Complications

• Minor hematuria or small perirenal hematoma; pooled minor bleeding 18.2%
• Renal capsular perforation or limited venographic extravasation; approximately 11% pooled
• Major renal hemorrhage requiring transfusion or intervention; pooled 4.5%
• Gross hematuria with clot retention or obstructive hydronephrosis
• Renal pseudoaneurysm or arteriovenous fistula
• Renal-vein thrombosis
• Contrast-associated acute kidney injury
• Jugular-access or cardiopulmonary complication

Exam pearls

• Percutaneous biopsy remains first line; TJRB is a high-risk or technically difficult alternative.
• The usual route is right internal jugular vein to IVC to right renal vein to a peripheral lower-pole cortical vein.
• Use a posterolateral cortical trajectory and avoid the renal hilum, collecting system and colon.
• Adequacy means cortex with glomeruli correctly distributed for LM, IF and EM, not merely a long core.
• Check venography after each pass; isolated capsular perforation may be self-limited and does not mandate routine embolization.
• Preserve venous access until persistent extravasation has been excluded or treated.
• TJRB lowers bleeding risk in selected high-risk patients but does not eliminate the possibility of transfusion or renal arterial embolization.

Viva questions

What is the principal indication for transjugular renal biopsy?

It is used for non-targeted renal cortical biopsy when histology is necessary but percutaneous biopsy is contraindicated, unsafe, technically impossible or has failed. Typical reasons are coagulopathy, thrombocytopenia, unavoidable antithrombotic therapy, morbid obesity, ascites or inability to tolerate prone positioning.

Why is the right renal vein and lower pole usually preferred?

The right renal vein is short and usually offers a favorable course from the IVC. A peripheral lower-pole vein permits a posterolateral cortical trajectory away from the hilum and larger vessels.

Why may the transjugular route be safer in a bleeding-prone patient?

The biopsy is directed from a renal vein into cortex, so much of the bleeding can decompress into the low-pressure venous system rather than directly into the retroperitoneum. However, capsular or arterial perforation can still produce major hemorrhage, so TJRB is not a bloodless procedure.

What tissue processing must be planned before renal biopsy?

Cortical tissue containing glomeruli must be allocated for light microscopy, immunofluorescence and electron microscopy. The renal pathologist should define the local media and triage scant tissue; placing all cores in formalin is a critical error.

How do you detect and manage capsular perforation?

Perform a low-pressure check venogram after each pass. Isolated stable capsular staining often needs observation only, but persistent extravasation, hematuria or hemodynamic change requires tract or venous-branch embolization and assessment for an arterial injury.

What are the pooled diagnostic yield and major bleeding rate?

The 2020 systematic review reported diagnostic tissue in **90.3%** of procedures. Major bleeding requiring transfusion or another invasive intervention occurred in **4.5%**, while minor bleeding occurred in **18.2%**.

Is coagulopathy an absolute contraindication to transjugular renal biopsy?

No. Coagulopathy is often the reason for choosing TJRB, but reversible abnormalities should still be optimized and the residual risk assessed. Target renal-vein thrombosis, uncontrolled hypertension and lack of a safe venous route are more important reasons not to proceed.

References